Review studies evaluating bevacizumab plus irinotecan. Tables reported that 10 studies evaluated bevacizumab plus irinotecan and provided 11 cohorts (n=411 patients). Sample size ranged from 13 to 82.
For patients who received bevacizumab plus irinotecan, median progression-free survival time ranged from 2.4 to 13.4 months, median overall survival ranged from 6.2 to 14.9 months and response rates ranged from 28% to 86%. The most common side effects were haemorrhage, thromboembolic complications and gastrointestinal toxicities.
Data from the existing database (reported as containing data from 741 cohorts from 1973; these patients appeared to have high grade glioma) reported median overall survival for all cohorts was 13.7 months and the one-year survival rate was 18.9%. For adults with recurrent high-grade glioma (282 cohorts), mean median survival time was 10.96 months. Mean response rate in patients with recurrent glioma appeared to be 18.9%.
Bevacizumab plus irinotecan treatment improved response rate (p=0.00002) and survival (p=0.024) compared to other treatments. There were insufficient data to evaluate effects of progression-free survival.